Inge Juul Sørensen

FRI0190 Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry

B. Glintborg, M. Hetland, S. Chrysidis, 2017 .

Occurrence and Prediction of Flare After Tapering of Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis

H. Røgind, M. Hetland, K. Gosvig, 2023, The Journal of Rheumatology.

Comparing patient-reported outcomes entered at home versus at hospital, and testing touch screens for initial recruitment to scientific trials in arthritis patients

R. Christensen, B. Glintborg, M. Hetland, 2018, Scandinavian journal of rheumatology.